Clinical Trial Update: An Open-label Dose Escalation and Expansion, Followed by a Phase II Study of Tulmimetostat (DZR123) and JSB462 (Luxdegalutamide) in Patients With Progressive Metastatic Castrate Resistant Prostate Cancer (mCRPC) (TulmiSTAR-01) [Phase 1, Phase 2]

View source ↗

Summary

This document outlines a two-part clinical trial (Phase 1 dose escalation/expansion followed by Phase 2) of Tulmimetostat and Luxdegalutamide (JSB462) in progre…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• Luxdegalutamide (Luxdegalutamide)
• Tulmimetostat (Tulmimetostat)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Progressive Metastatic Castrate Resistant Prostate Cancer | Phase 1, Phase 2 | Status: RECRUITING